Access the full text.
Sign up today, get DeepDyve free for 14 days.
D. Quinn, J. Nemunaitis, J. Fuloria, C. Britten, N. Gabrail, L. Yee, M. Acharya, Kai Chan, Nadine Cohen, A. Dudov (2009)
Effect of the Cytochrome P450 2C19 Inhibitor Omeprazole on the Pharmacokinetics and Safety Profile of Bortezomib in Patients with Advanced Solid Tumours, Non-Hodgkin’s Lymphoma or Multiple MyelomaClinical Pharmacokinetics, 48
A. Hemeryck, R. Geerts, J. Monbaliu, S. Hassler, T. Verhaeghe, L. Diels, W. Verluyten, L. Beijsterveldt, R. Mamidi, C. Janssen, R. Coster (2007)
Tissue distribution and depletion kinetics of bortezomib and bortezomib-related radioactivity in male rats after single and repeated intravenous injection of 14C-bortezomibCancer Chemotherapy and Pharmacology, 60
Alexander Arlt, I. Bauer, C. Schafmayer, J. Tepel, S. Müerköster, M. Brosch, C. Röder, H. Kalthoff, J. Hampe, M. Moyer, U. Fölsch, H. Schäfer (2009)
Increased proteasome subunit protein expression and proteasome activity in colon cancer relate to an enhanced activation of nuclear factor E2-related factor 2 (Nrf2)Oncogene, 28
N. Helsby, W. Lo, K. Sharples, G. Riley, M. Murray, K. Spells, M. Dzhelai, A. Simpson, M. Findlay (2008)
CYP2C19 pharmacogenetics in advanced cancer: compromised function independent of genotypeBritish Journal of Cancer, 99
M. Danhof (2016)
Systems pharmacology - Towards the modeling of network interactions.European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences, 94
C. Jakob, K. Egerer, P. Liebisch, S. Türkmen, I. Zavrski, U. Kuckelkorn, U. Heider, M. Kaiser, C. Fleissner, J. Sterz, L. Kleeberg, E. Feist, G. Burmester, P. Kloetzel, O. Sezer (2007)
Circulating proteasome levels are an independent prognostic factor for survival in multiple myeloma.Blood, 109 5
J. Adams, M. Kauffman (2004)
Development of the Proteasome Inhibitor Velcade™ (Bortezomib)Cancer Investigation, 22
J. Chien, C. Banfield, R. Brazzell, P. Mayer, J. Slattery (1992)
Saturable Tissue Binding and Imirestat Pharmacokinetics in RatsPharmaceutical Research, 9
H. Fuchs, J. Tillement, S. Urien, A. Greischel, W. Roth (2009)
Concentration‐dependent plasma protein binding of the novel dipeptidyl peptidase 4 inhibitor BI 1356 due to saturable binding to its target in plasma of mice, rats and humansJournal of Pharmacy and Pharmacology, 61
V. Uttamsingh, Chuang Lu, G. Miwa, L. Gan (2005)
RELATIVE CONTRIBUTIONS OF THE FIVE MAJOR HUMAN CYTOCHROMES P450, 1A2, 2C9, 2C19, 2D6, AND 3A4, TO THE HEPATIC METABOLISM OF THE PROTEASOME INHIBITOR BORTEZOMIBDrug Metabolism and Disposition, 33
N. Hosea, W. Collard, S. Cole, T. Maurer, Rick Fang, H. Jones, S. Kakar, Y. Nakai, Bill Smith, R. Webster, K. Beaumont (2009)
Prediction of Human Pharmacokinetics From Preclinical Information: Comparative Accuracy of Quantitative Prediction ApproachesThe Journal of Clinical Pharmacology, 49
G. Levy (1994)
Pharmacologic target‐mediated drug dispositionClinical Pharmacology & Therapeutics, 56
G. An (2017)
Small‐Molecule Compounds Exhibiting Target‐Mediated Drug Disposition (TMDD): A MinireviewThe Journal of Clinical Pharmacology, 57
M. Boccadoro, Gareth Morgan, James Cavenagh (2005)
Preclinical evaluation of the proteasome inhibitor bortezomib in cancer therapyCancer Cell International, 5
T. Pekol, J. Daniels, J. Labutti, I. Parsons, D. Nix, E. Baronas, F. Hsieh, L. Gan, G. Miwa, L. G (2005)
HUMAN METABOLISM OF THE PROTEASOME INHIBITOR BORTEZOMIB: IDENTIFICATION OF CIRCULATING METABOLITESDrug Metabolism and Disposition, 33
M. Majetschak, L. Sorell (2008)
Immunological methods to quantify and characterize proteasome complexes: development and application.Journal of immunological methods, 334 1-2
J. Khal, A. Hine, K. Fearon, C. Dejong, M. Tisdale (2005)
Increased expression of proteasome subunits in skeletal muscle of cancer patients with weight loss.The international journal of biochemistry & cell biology, 37 10
H. Cubitt, J. Houston, A. Galetin (2011)
Prediction of Human Drug Clearance by Multiple Metabolic Pathways: Integration of Hepatic and Intestinal Microsomal and Cytosolic DataDrug Metabolism and Disposition, 39
K. Venkatakrishnan, M. Rader, R. Ramanathan, S. Ramalingam, E. Chen, W. Riordan, W. Trepicchio, M. Cooper, M. Karol, L. Moltke, R. Neuwirth, M. Egorin, G. Chatta (2009)
Effect of the CYP3A inhibitor ketoconazole on the pharmacokinetics and pharmacodynamics of bortezomib in patients with advanced solid tumors: a prospective, multicenter, open-label, randomized, two-way crossover drug-drug interaction study.Clinical therapeutics, 31 Pt 2
P. Zhao, I. Ragueneau-Majlessi, Lei Zhang, J. Strong, K. Reynolds, R. Levy, K. Thummel, Shiew-Mei Huang (2009)
Quantitative Evaluation of Pharmacokinetic Inhibition of CYP3A Substrates by Ketoconazole: A Simulation StudyThe Journal of Clinical Pharmacology, 49
Li Zhang, D. Mager (2015)
Physiologically-based pharmacokinetic modeling of target-mediated drug disposition of bortezomib in miceJournal of Pharmacokinetics and Pharmacodynamics, 42
E. Kupperman, Edmund Lee, Yueying Cao, Bret Bannerman, Michael Fitzgerald, A. Berger, Jie Yu, Yu Yang, P. Hales, F. Bruzzese, Jane Liu, J. Blank, Khristofer Garcia, C. Tsu, L. Dick, P. Fleming, Li Yu, M. Manfredi, M. Rolfe, J. Bolen (2010)
Evaluation of the proteasome inhibitor MLN9708 in preclinical models of human cancer.Cancer research, 70 5
Peter Bross, R. Kane, A. Farrell, S. Abraham, K. Benson, M. Brower, Sean Bradley, J. Gobburu, A. Goheer, Shwu-Luan Lee, J. Leighton, C. Liang, R. Lostritto, W. Mcguinn, D. Morse, Atiqur Rahman, L. Rosario, S. Verbois, G. Williams, Yong-cheng Wang, R. Pazdur (2004)
Approval Summary for Bortezomib for Injection in the Treatment of Multiple MyelomaClinical Cancer Research, 10
J. Adams (2004)
The development of proteasome inhibitors as anticancer drugs.Cancer cell, 5 5
B. Davies, T. Morris (1993)
Physiological Parameters in Laboratory Animals and HumansPharmaceutical Research, 10
Leibman Kc (1973)
Editorial: Drug Metabolism and Disposition: the biological fate of chemicals.Drug metabolism and disposition: the biological fate of chemicals, 1 2
G. An, Wei Liu, D. Katz, G. Marek, W. Awni, S. Dutta (2014)
Population pharmacokinetics of the 11β‐hydroxysteroid dehydrogenase type 1 inhibitor ABT‐384 in healthy volunteers following single and multiple dose regimensBiopharmaceutics & Drug Disposition, 35
D. Reece, D. Sullivan, S. Lonial, A. Mohrbacher, G. Chatta, C. Shustik, Howard Burris, K. Venkatakrishnan, R. Neuwirth, W. Riordan, M. Karol, L. Moltke, M. Acharya, P. Zannikos, A. Stewart (2010)
Pharmacokinetic and pharmacodynamic study of two doses of bortezomib in patients with relapsed multiple myelomaCancer Chemotherapy and Pharmacology, 67
A. Hellmann, S. Rule, J. Walewski, O. Shpilberg, Huaibao Feng, H. Velde, Hamina Patel, D. Skee, S. Girgis, V. Louw (2011)
Effect of Cytochrome P450 3A4 Inducers on the Pharmacokinetic, Pharmacodynamic and Safety Profiles of Bortezomib in Patients with Multiple Myeloma or Non-Hodgkin’s LymphomaClinical Pharmacokinetics, 50
DE Coutant, P. Kulanthaivel, P. Turner, Robert Bell, J. Baldwin, S. Wijayawardana, C. Pitou, Stephen Hall (2015)
Understanding Disease–Drug Interactions in Cancer Patients: Implications for Dosing Within the Therapeutic WindowClinical Pharmacology & Therapeutics, 98
P. LoRusso, K. Venkatakrishnan, R. Ramanathan, J. Sarantopoulos, D. Mulkerin, S. Shibata, A. Hamilton, A. Dowlati, S. Mani, M. Rudek, C. Takimoto, R. Neuwirth, D. Esseltine, P. Ivy (2012)
Pharmacokinetics and Safety of Bortezomib in Patients with Advanced Malignancies and Varying Degrees of Liver Dysfunction: Phase I NCI Organ Dysfunction Working Group Study NCI-6432Clinical Cancer Research, 18
Publisher's Note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations
Bortezomib is a potent 20S proteasome inhibitor approved for the treatment of multiple myeloma and mantle cell lymphoma. Despite the extensive clinical use of bortezomib, the mechanism of the complex time-dependent pharmacokinetics of bortezomib has not been fully investigated in context of its pharmacodynamics (PD) and drug–drug interaction (DDI) profiles. Here, we aimed to develop a mechanistic physiologically based (PB) PK/PD model to project PK, blood target inhibition and DDI of bortezomib in patients. A minimal PBPK/PD model consisting of six compartments was constructed using a bottom–up approach with pre-clinical data and human physiological parameters. Specifically, the target-mediated drug disposition (TMDD) of bortezomib in red blood cells (RBC), which determines target inhibition in blood, was characterized by incorporating the proteasome binding affinity of bortezomib and the proteasome concentration in RBC. The hepatic clearance and fraction metabolized by different CYP isoforms were estimated from in vitro metabolism and phenotyping experiments. The established model adequately characterized the multi-exponential and time-dependent plasma pharmacokinetics, target binding and blood proteasome inhibition of bortezomib. Further, the model was able to accurately predict the impact of a strong CYP3A inducer (rifampicin) and inhibitor (ketoconazole) on bortezomib exposure. In conclusion, the mechanistic PBPK/PD model successfully described the complex pharmacokinetics, target inhibition and DDIs of bortezomib in patients. This study illustrates the importance of incorporating target biology, drug–target interactions and in vitro clearance parameters into mechanistic PBPK/PD models and the utility of such models for pharmacokinetic, pharmacodynamic and DDI predictions.
"The AAPS Journal" – Springer Journals
Published: Apr 14, 2020
Read and print from thousands of top scholarly journals.
Already have an account? Log in
Bookmark this article. You can see your Bookmarks on your DeepDyve Library.
To save an article, log in first, or sign up for a DeepDyve account if you don’t already have one.
Copy and paste the desired citation format or use the link below to download a file formatted for EndNote
Access the full text.
Sign up today, get DeepDyve free for 14 days.
All DeepDyve websites use cookies to improve your online experience. They were placed on your computer when you launched this website. You can change your cookie settings through your browser.